Colette Brady

Partner

Colette is a Partner in our Litigation & Investigations Department and a member of our Life Sciences and Intellectual Property Groups specialising in intellectual property and regulatory law, dealing with both contentious and non-contentious matters.

Colette Brady

Recent significant cases and advisory work includes representing/advising:

  • Genentech Inc in Commercial Court proceedings against Amgen relating to Amgen’s product Mvasi®, a biosimilar of Genentech’s leading cancer drug Avastin®.
  • Clonmel Healthcare Limited (Irish subsidiary of STADA Arzneimittel AG) in the defence of Commercial Court proceedings issued by Merck Sharpe & Dohme (MSD) with both the preliminary injunction proceedings and substantive proceedings being appealed to the Supreme Court.
  • MSD in defence of Commercial Court proceedings brought by Bristol Myers Squibb for patent infringement and MSD’s counterclaim for invalidity. This case related to anti-PD-1 antibodies in the field of cancer therapy and MSD’s product Keytruda.
  • Some of the world’s leading social media and content-sharing platforms and ISPs on copyright strategy.
  • Vacaciones eDreams (one of Europe’s biggest online travel agencies) in trade mark infringement, passing off and competition law proceedings before the Commercial Court issued by Ryanair against our client and Google.
  • Uniphar in respect of its defence of trade mark infringement proceedings issued before the Commercial Court.
  • Guerbet SA in relation Guerbet’s acquisition of Mallinckrodt’s Irish CMDS business in a transaction valued at approximately $270m.
Colette is a regular contributor of articles to publications and is a lecturer in IP on the Law Society’s Diploma and Certificate Programmes. Colette is also a registered Irish and European Trade Mark and Design Attorney.

 

Ranking & Recommendations

Related Knowledge

Article and Insights
24
May 2023
Colette Brady and Florence Meagher of the William Fry Food, Beverage and Agribusin...
Partner
Colette Brady
Article and Insights
28
Apr 2023
The Court of Appeal has ruled in favour of Biogen, overturning the High Court's de...
Partner
Laura Scott
Article and Insights
3
Jan 2023
New CJEU guidance on rebranding parallel imported medicines.
Partner
Charleen O’Keeffe
Article and Insights
19
Dec 2022
General Court finds that evidence of use of an earlier EU trade mark in the UK is ...
Partner
Charleen O’Keeffe
Article and Insights
21
Nov 2022
A new EU regulation requiring wine labels to contain a nutrition declaration and a...
Partner
Elaine Morrissey
Article and Insights
30
Sep 2022
In this article we round-up the key measures and supports for the agri-business se...
Partner
Elaine Morrissey
Article and Insights
7
Jul 2022
In an appeal challenging the marketing authorisation of a generic drug, the Court ...
Partner
Charleen O’Keeffe
Article and Insights
7
Jul 2022
The Irish Pharmaceutical Healthcare Association removes reference to 'medical devi...
Partner
Charleen O’Keeffe
Article and Insights
4
Jul 2022
On 28 June 2022, the Government issued a press release reaffirming its commitment ...
Partner
Charleen O’Keeffe
Article and Insights
31
May 2022
The In Vitro Diagnostic Medical Device Regulation, (EU) 2017/746, is fully applica...
Partner
Charleen O’Keeffe